Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

COVID-19 vaccine

- PMLiVE

Pfizer announces phase 3 results for potential non-small cell lung cancer treatment

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

- PMLiVE

Pfizer and Innovent Biologics agree on deal worth up to $10.5bn

The companies plan to research and develop 12 new cancer treatments

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

- PMLiVE

Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE

Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

Pfizer agrees pricing and distribution deal with US government

The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi

Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links